Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sue Gail Eckhardt Insider Profile
4 Followers
Sue Gail Eckhardt, Director at Syros Pharmaceuticals, holds 30.41K shares in Exelixis (Ticker: EXEL), holds 16.00K shares in Syros Pharmaceuticals (Ticker: SYRS).
Sue Gail Eckhardt has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Sue Gail Eckhardt holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Sue Gail Eckhardt
Sue Gail Eckhardt's Trading History
Syros Pharmaceuticals
Jun 07, 2024
Director
Uninformative Buy
―
$2.78K
Exelixis
Feb 19, 2025
Director
Uninformative Buy
179.23K
$1.12M
List of latest transactions for each holding click on a transaction to see Sue Gail Eckhardt's performance on stock
You May Also Like
Sue Gail Eckhardt insider profile FAQ
What is the percentage of profitable transactions made by Sue Gail Eckhardt?
The percentage of profitable transactions made by Sue Gail Eckhardt is ―.
What is the average return per transaction made by Sue Gail Eckhardt?
The average return per transaction made by Sue Gail Eckhardt is ―.
What stocks does Sue Gail Eckhardt hold?
Sue Gail Eckhardt holds: SYRS, EXEL stocks.
What was Sue Gail Eckhardt’s latest transaction?
Sue Gail Eckhardt latest transaction was an Uninformative Buy of $179.23K.
What was Sue Gail Eckhardt's most profitable transaction?
Sue Gail Eckhardt’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Sue Gail Eckhardt's role in Syros Pharmaceuticals?
Sue Gail Eckhardt's role in Syros Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.